About PharmCube

PharmCube

PharmCube (Chinese: 医药魔方) is a Beijing-based pharmaceutical data and intelligence company founded in 2015. It operates a big-data and artificial intelligence platform covering the full lifecycle of pharmaceutical products, integrating and standardising global data on drug research and development, clinical trials, patents, regulatory approvals, licensing deals and sales. Where a drug developer, an investor or a government department once had to assemble that picture from regulatory filings, patent offices, trial registries, journals and market reports in many languages, PharmCube sells it as a connected set of databases, supplemented by media and consulting services. Its data is now cited well beyond its subscriber base: financial reporting on China's innovative-drug licensing boom, for example, draws on PharmCube figures, and the company's own anniversary research series has become a reference on a decade of Chinese pharmaceutical deal-making.

Founding and Company Profile

PharmCube was founded in 2015 and is legally PharmCube (Beijing) Co., Ltd., with its official website at pharmcube.com and an English-language global site presenting its products to international users. Company directories such as Preqin record it as established in 2015 and based in Beijing, providing pharmaceutical data products and services for pharmaceutical companies and investment institutions, as well as data monitoring and research support for government departments. The company says it applies artificial intelligence technology, including natural language processing and machine learning, to the problem of pharmaceutical information, and that its teams consist of medical and pharmaceutical professionals alongside data specialists. Its investors have included Wind Information, the Chinese financial data provider, Legend Star and China Renaissance — backers whose presence connects the company to both the financial-data industry and China's technology investment community.

The Full-Lifecycle Data Model

PharmCube's organising idea is the lifecycle of a drug. In its own description, the company has built an exclusive data standardising system, based on artificial intelligence, to integrate data across the entire pharmaceutical industry chain: investment and financing, the patent application landscape, market competition, clinical research, registration and approval, market access, sales and evidence-based medicine. That sequence runs from the earliest decision to fund or start a programme through discovery, trials and approval to the product's commercial performance in hospitals and pharmacies. Because the same standardised identifiers for drugs, targets, diseases and companies run through each stage, a user can follow a single asset from a patent filing to a licensing deal to its sales in Chinese hospitals — the connection between stages being the product's main claim to usefulness.

NextBiopharm: The Innovative-Drug Database

The flagship product is NextBiopharm, a global innovative-drug database. PharmCube says NextBiopharm highly integrates and standardises patent, registration, literature, clinical trial, news, deal and marketing information on innovative drugs worldwide, with what it calls the best coverage of the China market, and it is connected to the company's other databases so users can move across the full lifecycle. The official site has reported coverage of more than 111,000 drugs, 19,000 companies, 8,200 targets and 3,700 diseases. The product is built around the questions drug developers ask when starting or positioning a project: it monitors information sources including leading regulatory agencies worldwide and comprehensive news sources, offers ten screening dimensions for project selection, and includes a clinical results module collecting newly released information from pivotal trials and a news and trends module combining global biopharmaceutical headlines with PharmCube's monthly reports. Field analysis and target heat maps are intended to help users avoid excessive competition among product candidates working on the same target or disease.

PharmaGO and TrialCube: Warehouse and Clinical Trials

Alongside NextBiopharm, PharmaGO is presented as a one-stop drug data warehouse, giving users a single access point to the underlying drug data rather than a single analytical view. For clinical research specifically, the company offers TrialCube, described on its global site as providing insights into the global clinical trial landscape. Clinical trials are the point in a drug's life where public information is richest and most consequential — registrations, enrolments, endpoints and results announcements all shape competitors' and investors' decisions — and PharmCube's trial data connects to the same drug, company and disease records used elsewhere in the family, so a trial can be read in the context of the asset's patents, deals and eventual approval status. Preqin's profile of the company also lists a medical evidence-based database, NextMed, among its products, reflecting the evidence-based medicine strand of its data model.

NextPat and NextBioSeq: Patents and Sequences

Two products serve the intellectual property side of drug development. NextPat is a pharmaceutical patent platform offering one-stop patent search, analysis and monitoring services. PharmCube says it covers more than 40 million pieces of patent data from more than 100 countries and regions, updated weekly, and uses artificial intelligence technologies such as natural language processing and knowledge graphs to integrate patents with data on drugs, targets, diseases, companies, people and technologies into a patent intelligence system. It presents international patents in both English and Chinese, which the company says reduces the cost of patent retrieval and examination for Chinese users working with foreign filings. NextBioSeq, launched in 2022, is a biological sequence query platform: it mines and cleans nucleotide and protein sequences from patents, papers and biological databases, collecting, by the company's account, more than 400 million pieces of patent-related sequence data from three major biological databases and five intellectual property administrations, so that researchers can search for products with similar sequences and identify development risks earlier.

PharmaBI: Sales Data for the China Market

For the commercial end of the lifecycle, the PharmaBI family tracks drug sales in China. Its hospital channel product draws monthly data from more than 2,200 hospitals in 342 Chinese cities, and the family's customised hospital market product is built on Microsoft PowerBI to offer interactive visualisation of multi-dimensional sales data. The wider PharmaBI range includes a China hospital drug sales database, a China retail pharmacy drug sales database, a customised service for China's hospital pharmaceutical markets and a retail channel competitive product monitoring platform. Sales data of this kind is what turns research intelligence into market intelligence: a company can compare its product's hospital performance with competitors', city by city and month by month, rather than relying on annual estimates. PharmCube says its hospital products help users avoid problems of inconsistent data, unknown sources and inconsistent indicators by drawing the channel data into one standardised system.

MedAlpha and Investment Data

PharmCube also serves the investment community directly. MedAlpha is its database of healthcare investment and financing — in its current global presentation, global innovative-drug investment and financing data — recording who raised money, on what terms and at what stage. Its newer InvestGO database is the source the company itself uses in published analysis of innovative-drug financing trends; a PharmCube report drawing on InvestGO charted how early-stage funding changed after 2022, with 2024 deal flow falling back to levels last seen in 2018. Together with the deal records inside NextBiopharm, this gives investors a view that runs from venture rounds in private Chinese biotech companies to the cross-border licensing transactions that have become a defining feature of the industry.

Consulting, Media and Research Reports

Data subscriptions are only part of the business. PharmCube describes its offer as data, media and consulting services. Its consulting practice lists six services: competition landscape and development planning, clinical evaluation and promotion strategy, market potential assessment and valuation, product pipeline screening and planning, pricing and market access policies, and industry and competitor research. Its media operation publishes news and reports through its global site and Chinese channels, including monthly global drug progress reports and annual analyses such as its top drug targets lists. For its tenth anniversary the company issued a research series reviewing a decade of China's innovative drug industry, including a report on China's innovative drug transactions from 2015 to 2024 that drew on ten years of transaction data from its databases to examine deal volumes, the evolution of deal models and key participants — an example of the company's databases being used to write the industry's recent history.

Clients and Partnerships

PharmCube serves pharmaceutical companies, investment institutions and government departments, and deal directories describe partnerships with nearly a thousand leading pharmaceutical companies and investment institutions. Preqin records cooperation with Yeehong Business School, Endpoints News and Mei Zhong Yao Yuan, and the company's global site presents a partnership with Endpoints, the United States biopharmaceutical news organisation — a link that reflects its ambition to be read outside China as well as within it. Government use is a distinctive strand: the company provides data monitoring and research support for government departments concerned with the pharmaceutical industry, alongside its commercial subscriber base of drug developers and investors.

Place in China's Pharmaceutical Data Industry

PharmCube's growth since 2015 has tracked the transformation of its market. China moved in that decade from a pharmaceutical industry centred on generics to one producing innovative drugs that global companies license in large numbers, and every participant in that shift — developers choosing targets, investors pricing pipelines, officials monitoring the sector — needs standardised, current information across patents, trials, approvals, deals and sales. PharmCube built its platform to supply exactly that, product by product, from NextBiopharm's innovative-drug records to PharmaBI's monthly hospital sales. A directory of information agencies lists it as a data company rather than a drug developer: its product is the map of the industry, not the medicines, and the widening citation of its figures in international financial reporting suggests the map is increasingly the one the industry uses.